Unique Challenges Faced by a Child with Standard Risk Leukemia in Post-COVID Era: A Case Report
Swati Bhayana1, Manas Kalra1, Pallavi Sachdeva2
1Department of Pediatric Hematology Oncology and BMT Unit, Sir Ganga Ram Hospital, New Delhi, India.
Summary
Children with acute lymphoblastic leukemia face unique post-COVID-19 challenges. This case report highlights rare complications during standard leukemia treatment, urging vigilance among pediatric oncologists and intensive care specialists.
Area of Science:
- Pediatric Oncology
- Infectious Disease Complications
- Hematologic Malignancies
Background:
- The post-COVID-19 era presents evolving challenges for pediatric cancer patients.
- Standard acute lymphoblastic leukemia (ALL) treatment protocols may be complicated by novel disease-related or treatment-related issues.
- Understanding these new complexities is crucial for effective patient management.
Observation:
- A case of a child undergoing treatment for acute lymphoblastic leukemia (ALL) experienced an unusually prolonged and complicated illness course.
- The observed complications were atypical for standard ALL therapy.
- This presentation underscores the need for heightened awareness of potential post-viral sequelae in immunocompromised children.
Findings:
- Protracted illness course in a pediatric ALL patient during the post-COVID-19 period.
- Uncommon complications arose despite adherence to standard leukemia treatment protocols.
- The case illustrates the potential for unique challenges in pediatric oncology in the current era.
Implications:
- Pediatric oncologists and intensive care specialists must be prepared for atypical complications in children with malignancies, particularly in the post-COVID-19 context.
- This case serves as a critical reminder to consider novel complications that may arise during or after standard cancer therapy.
- Enhanced vigilance and adaptive treatment strategies are necessary to manage these emerging challenges in pediatric cancer care.
Related Concept Videos
Bone Marrow Sampling and Transplants
489
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
489
Immunodeficiency Diseases
1.2K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
There are three main causes of immunodeficiency...
1.2K
Disorders of Leukocytes
1.1K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
1.1K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Pneumonia III: Complications and Assessment
422
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
422
Rous Sarcoma Virus (RSV) and Cancer
5.3K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.3K


